DOI QR코드

DOI QR Code

Apixaban versus Warfarin in Patients with Chronic Kidney Disease; A Systematic Review and Meta-analysis

만성신장병환자에서 apixaban과 warfarin의 안전성 비교: 체계적 문헌고찰 및 메타분석

  • Nam, Jae Hyun (College of Pharmacy and Institute of Pharmaceutical Science and Technology, Hanyang University) ;
  • Kim, Chae Young (College of Pharmacy and Institute of Pharmaceutical Science and Technology, Hanyang University) ;
  • Lee, Yoo Kyung (College of Pharmacy and Institute of Pharmaceutical Science and Technology, Hanyang University) ;
  • Jung, Da Woom (College of Pharmacy and Institute of Pharmaceutical Science and Technology, Hanyang University) ;
  • Gwak, Hye Young (Department of Pharmacy, Hanyang University Hospital) ;
  • Chung, Jee Eun (College of Pharmacy and Institute of Pharmaceutical Science and Technology, Hanyang University)
  • Received : 2021.04.28
  • Accepted : 2021.06.10
  • Published : 2021.06.30

Abstract

Background: Patients with chronic kidney disease (CKD) are at a high risk of stroke-related morbidity, mortality, and bleeding. However, the overall risk/benefit of anticoagulant therapy among patients with CKD remains unclear. Methods: The MEDLINE, EMBASE, and CENTRAL databases were comprehensively searched until July 31, 2020, to investigate the safety and efficacy of apixaban in patients with stage 4 or 5 CKD, as compared with warfarin. The primary outcome was an incidence of major bleeding. Secondary outcomes included composite bleeding (major, clinically relevant, and minor bleeding), venous thromboembolism (VTE), stroke, and death. Results: In total, seven studies consisting of 10,816 patients were included. Compared with warfarin, apixaban was associated with a reduced risk of major bleeding (OR 0.49, 95% CI 0.41-0.58). In terms of composite bleeding, apixaban tended to pose a significantly lower risk than warfarin (OR 0.51, 95% CI 0.37-0.71). There was no difference between apixaban and warfarin with respect to the risk of stroke or death (stroke: OR 1.23, 95% CI 0.49-3.12; death: OR 0.73, 95% CI 0.45-1.18). Conclusion: Among patients with stage 4 or 5 CKD, the use of apixaban was associated with a lower risk of bleeding compared to warfarin and was also found to pose no excess risk of thromboembolic events.

Keywords

Acknowledgement

본 연구는 한국연구재단(과제번호: NRF-2018R1D1A1B07049959) 및 과학기술정보통신부 정보통신기획평가단(과제번호: 2020-0-01343, 인공지능융합센터, 한양대학교 ERICA) 지원을 받아 수행되었으므로 이에 감사드립니다.

References

  1. January CT, Wann LS, Calkins H, et al. 2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society in Collaboration With the Society of Thoracic Surgeons. Circulation 2019;140(2):e125-e51.
  2. Pengo V, Banzato A, Bison E, et al. Efficacy and safety of rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome: Rationale and design of the Trial on Rivaroxaban in AntiPhospholipid Syndrome (TRAPS) trial. Lupus 2016;25(3):301-6. https://doi.org/10.1177/0961203315611495
  3. Martin K, Beyer-Westendorf J, Davidson B, et al. Use of the direct oral anticoagulants in obese patients: guidance from the SSC of the ISTH. J Thromb Haemost 2016;14(6):1308-13. https://doi.org/10.1111/jth.13323
  4. Chagnac A, Weinstein T, Korzets A, et al. Glomerular hemodynamics in severe obesity. Am J Physiol Renal Physiol 2000;278(5):F817-22. https://doi.org/10.1152/ajprenal.2000.278.5.F817
  5. Tobenkin A, Mohamoud M, Munoz M, et al. Direct oral anticoagulants and menorrhagia in premenopausal women: data from the food and drug administration adverse event reporting system and US drug utilization. Haemophilia 2017;23(Suppl 3):43.
  6. Braekkan S, Van Der Graaf Y, Visseren F, et al. Obesity and risk of bleeding: the SMART study. J Thromb Haemost 2016;14(1):65-72. https://doi.org/10.1111/jth.13184
  7. Potpara TS, Ferro C, Lip GY, et al. Management of atrial fibrillation in patients with chronic kidney disease in clinical practice: a joint European Heart Rhythm Association (EHRA) and European Renal Association/European Dialysis and Transplantation Association (ERA/EDTA) physician-based survey. Europace 2020;22(3):496-505. https://doi.org/10.1093/europace/euz358
  8. SAVAYSA(TM) oral tablets, edoxaban oral tablets. Daiichi, Sankyo. [Updated: 2015 January; cited 2020 July] Available from https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/206316lbl.pdf. Accessed March 1, 2021.
  9. Sohal AS, Gangji AS, Crowther MA, et al. Uremic bleeding: pathophysiology and clinical risk factors. Thromb Res 2006; 118(3):417-22. https://doi.org/10.1016/j.thromres.2005.03.032
  10. Ahuja T, Sessa K, Merchan C, et al. Oral factor Xa inhibitors versus warfarin for the treatment of venous thromboembolism in advanced chronic kidney disease. Adv Hematol 2021;2021:8870015.
  11. Ghoshal S, Freedman BI. Mechanisms of stroke in patients with chronic kidney disease. Am J Nephrol 2019;50(4):229-39. https://doi.org/10.1159/000502446
  12. Wattanakit K, Cushman M, Stehman-Breen C, et al. Chronic kidney disease increases risk for venous thromboembolism. J Am Soc Nephrol 2008;19(1):135-40. https://doi.org/10.1681/ASN.2007030308
  13. Wattanakit K, Cushrnan M. Chronic kidney disease increases risk for venous thromboembolism. Curr Opin Pulm Med 2009;15(5): 408-12. https://doi.org/10.1097/MCP.0b013e32832ee371
  14. Harel Z, Sholzberg M, Shah PS, et al. Comparisons between novel oral anticoagulants and vitamin K antagonists in patients with CKD. J Am Soc Nephrol 2014;25(3):431-42. https://doi.org/10.1681/ASN.2013040361
  15. Amani A, Fellers CM, Eyebe A, et al. Safety and efficacy of apixaban use in peritoneal dialysis: A review of the literature. Journal of Pharmacy Technology 2021;37(3):147-51. https://doi.org/10.1177/8755122520988728
  16. PRADAXA(R) oral capsules, dabigatran etexilate mesylate oral capsules. Boehringer Ingelheim. [Updated: April 2021; cited 2020 July]. Available from https://docs.boehringer-ingelheim.com/Prescribing%20Information/PIs/Pradaxa/Pradaxa.pdf. Accessed March 1, 2021.
  17. XARELTO(R) oral tablets, rivaroxaban oral tablets. Janssen. [Updated: January 2021; cited 2020 July] Available from https://www.janssenlabels.com/package-insert/product-monograph/ prescribing-information/XARELTO-pi.pdf. Accessed March 1, 2021.
  18. Parasrampuria DA, Truitt KE. Pharmacokinetics and pharmacodynamics of edoxaban, a non-vitamin K antagonist oral anticoagulant that inhibits clotting factor Xa. Clinical pharmacokinetics 2016;55(6):641-55. https://doi.org/10.1007/s40262-015-0342-7
  19. Turner RM, Bird SM, Higgins JP. The impact of study size on metaanalyses: examination of underpowered studies in Cochrane reviews. PloS one 2013;8(3):e59202. https://doi.org/10.1371/journal.pone.0059202
  20. Furlan AD, Malmivaara A, Chou R, et al. 2015 updated method guideline for systematic reviews in the Cochrane Back and Neck Group. Spine (Phila Pa 1976) 2015;40(21):1660-73. https://doi.org/10.1097/BRS.0000000000001061
  21. Herndon K, Guidry TJ, Wassell K, et al. Characterizing the safety profile of apixaban versus warfarin in moderate to severe chronic kidney disease at a veterans affairs hospital. Ann Pharmacother 2020;54(6):554-60. https://doi.org/10.1177/1060028019897053
  22. Reed D, Palkimas S, Hockman R, et al. Safety and effectiveness of apixaban compared to warfarin in dialysis patients. Res Pract Thromb Haemost 2018;2(2):291-8. https://doi.org/10.1002/rth2.12083
  23. Sarratt SC, Nesbit R, Moye R. Safety outcomes of apixaban compared with warfarin in patients with end-stage renal disease. Ann pharmacother 2017;51(6):445-50. https://doi.org/10.1177/1060028017694654
  24. Schafer JH, Casey AL, Dupre KA, et al. Safety and efficacy of apixaban versus warfarin in patients with advanced chronic kidney disease. Ann Pharmacother 2018;52(11):1078-84. https://doi.org/10.1177/1060028018781853
  25. Siontis KC, Zhang X, Eckard A, et al. Outcomes associated with apixaban use in patients with end-stage kidney disease and atrial fibrillation in the United States. Circulation 2018;138(15):1519-29. https://doi.org/10.1161/circulationaha.118.035418
  26. Stanifer JW, Pokorney SD, Chertow GM, et al. Apixaban versus warfarin in patients with atrial fibrillation and advanced chronic kidney disease. Circulation 2020;141(17):1384-92. https://doi.org/10.1161/CIRCULATIONAHA.119.044059
  27. Stanton BE, Barasch NS, Tellor KB. Comparison of the safety and effectiveness of apixaban versus warfarin in patients with severe renal impairment. Pharmacotherapy 2017;37(4):412-9. https://doi.org/10.1002/phar.1905
  28. Konstantinides SV, Meyer G, Becattini C, et al. 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS) Eur Heart J 2020;41(4):543-603. https://doi.org/10.1093/eurheartj/ehz405
  29. Lee CH, Lin TY, Chang SH, et al. Body mass index is an independent predictor of major bleeding in non-valvular atrial fibrillation patients taking dabigatran. Int J Cardiol 2017;228:771-8. https://doi.org/10.1016/j.ijcard.2016.11.277
  30. An SJ, Kim TJ, Yoon BW. Epidemiology, risk factors, and clinical features of intracerebral hemorrhage: an update. J Stroke 2017; 19(1):3-10. https://doi.org/10.5853/jos.2016.00864
  31. Chokesuwattanaskul R, Thongprayoon C, Tanawuttiwat T, et al. Safety and efficacy of apixaban versus warfarin in patients with endstage renal disease: Meta-analysis. Pacing Clin Electrophysiol 2018;41(6):627-34. https://doi.org/10.1111/pace.13331
  32. Abdullah HM, Ullah W, Jafar MS, et al. Safety and efficacy of apixaban, rivaroxaban, and warfarin in end-stage renal disease with atrial fibrillation: A systematic review and meta-analysis. Cardiovasc Revasc Med 2020;doi:10.1016/j.carrev.2020.09.041.
  33. Hanni C, Petrovitch E, Ali M, et al. Outcomes associated with apixaban vs warfarin in patients with renal dysfunction. Blood Advances 2020;4(11):2366-71. https://doi.org/10.1182/bloodadvances.2019000972
  34. Ionescu F, Cooper C, Petrescu I, et al. Safety of apixaban compared to warfarin in hemodialysis patients: Do antiplatelets make a difference? Eur J Haematol 2021;106(5):689-696. https://doi.org/10.1111/ejh.13599
  35. Garlo K, Mavrakanas T, Wang W, et al. Stroke and Major Bleeding when Switching from Warfarin to Apixaban in Patients with Advanced Chronic Kidney Disease and Prevalent Atrial Fibrillation. Available from https://assets.researchsquare.com/files/rs-144190/v1/a4beec1a-e42a-4efe-a1fa-3ed7af424ae9.pdf. Accessed March 1, 2021.
  36. Cho MS, Yun JE, Park JJ, et al. Pattern and impact of off-label underdosing of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation who are indicated for standard dosing. Am J Cardiol 2020;125(9):1332-8. https://doi.org/10.1016/j.amjcard.2020.01.044
  37. Labovitz AJ, Rose DZ, Fradley MG, et al. Early apixaban use following stroke in patients with atrial fibrillation: Results of the AREST trial. Stroke 2021;52(4):1164-71. https://doi.org/10.1161/STROKEAHA.120.030042